Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab

J Neurol. 2021 Oct;268(10):3592-3594. doi: 10.1007/s00415-021-10463-3. Epub 2021 Feb 27.

Authors

Mahsa Khayat-Khoei¹, Sarah Conway¹, Douglas A Rubinson², Petr Jarolim³, Maria K Houtchens⁴

Affiliations

¹ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
³ Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
⁴ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. mhoutchens@bwh.harvard.edu.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Antibody Formation
COVID-19 Vaccines
COVID-19*
Humans
SARS-CoV-2*
Vaccination

Substances

Antibodies, Monoclonal, Humanized
COVID-19 Vaccines
ocrelizumab